| Literature DB >> 35761326 |
Gloria Buffi1, Aurora Diotallevi2, Marcello Ceccarelli1, Federica Bruno3, Germano Castelli3, Fabrizio Vitale3, Mauro Magnani1, Luca Galluzzi1.
Abstract
BACKGROUND: Leishmaniases are a group of anthropo-zoonotic parasitic diseases caused by a protozoan of the Leishmania genus, affecting both humans and other vertebrates, including dogs. L. infantum is responsible for the visceral and occasionally cutaneous form of the disease in humans and canine leishmaniasis. Previously, we have shown that L. infantum induces a mild but significant increase in endoplasmic reticulum (ER) stress expression markers to promote parasites survival in human and murine infected macrophages. Moreover, we demonstrated that the miRNA hsa-miR-346, induced by the UPR-activated transcription factor sXBP1, was significantly upregulated in human macrophages infected with different L. infantum strains. However, the ER stress response in infected dogs, which represent an important reservoir for Leishmania parasite, was described once recently, whereas the miR-346 expression was not reported before. Therefore, this study aimed to investigate these pathways in the canine macrophage-like cell line DH82 infected by Leishmania spp. and to evaluate the presence of cfa-miR-346 in plasma of non-infected and infected dogs. The DH82 cells were infected with L. infantum and L. braziliensis parasites and the expression of cfa-mir-346 and several ER stress markers was evaluated by quantitative PCR (qPCR) at different time points. Furthermore, the cfa-miR-346 was monitored in plasma collected from non-infected dogs (n = 11) and dogs naturally infected by L. infantum (n = 18).Entities:
Keywords: Canine leishmaniasis; DH82; ER stress; Leishmania spp.; mir-346
Mesh:
Substances:
Year: 2022 PMID: 35761326 PMCID: PMC9235276 DOI: 10.1186/s12917-022-03359-5
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.792
Fig. 1Tunicamycin treatment induces ER stress markers but not cfa-mir-346 in DH82 cells. The ER stress expression markers resulted upregulated in DH82 cells treated with tunicamycin 2 µg/ml for 4 h (A), while the expression of cfa-miR-346 did not change significantly (B). Data are represented as the mean ± SD of technical replicates and are representative of two independent experiments. The graph shows the fold changes in comparison to the control (DMSO). Unpaired t-test with Welch's correction. *p < 0.05 **p < 0.01 ***p < 0.001
Infection indexes in DH82 cells
| Infection indexa | Infection indexa | |
|---|---|---|
| 143.3 ± 31.1 | 168.9 ± 58.8 | |
| 100.2 ± 22.1 | 92.7 ± 29.7 | |
| 130.0 ± 10.1 | 167.8 ± 25.8 | |
| 185.2 ± 31.2 | 94.0 ± 26.3 | |
| 189.9 ± 31.9 | 245.7 ± 50.5 |
acalculated by multiplying the percentage of infected macrophages by the average number of parasites per macrophage, means ± SD)
Fig. 2ER stress markers and mir-346 expression in infected DH82 cells. Gene expression of selected ER stress markers and cfa-miR-346 in DH82 cells infected with four L. (L.) infantum strains and one L. (V.) braziliensis strain after 24 h (A, B) and 48 h (C, D). Graphs show the fold changes related to the control (non-infected cells). Unpaired t-test with Welch's correction * p < 0.05 ** p < 0.01
Fig. 3mir-346 induction is related to Leishmania infection. cfa-miR-346 expression in DH82 cells infected with L. (L.) infantum MHOM/TN/80/IPT1 (A) and canine clinical isolate 42 (B) for 6 h, 24 h, 48 h. The graph shows the fold changes in comparison to non-infected cells (mean ± SD of two independent experiments). One-way ANOVA with Tukey’s Multiple Comparison Test. n.s.: not significant, **p < 0.01, ***p < 0.001
Fig. 4Relative amount of cfa-miR-346 in plasma of non-infected (n = 11) and infected dogs (n = 18). The scatter plot graph indicates the mean ± SD. Unpaired t-test with Welch's correction. ***p < 0.001
Canine sample ID, summary of clinical signs, and results of diagnostic methods
| Sample ID | Clinical signs | IFAT | SNAP TEST | qPCR (blood) | qPCR (Lymph node) | Parasite isolation | Diagnosis of leishmaniasis |
|---|---|---|---|---|---|---|---|
| 24 | Lymphadenomegaly | Neg | n.a | Neg | Neg | n.a | - |
| 29 | Neg | Neg | n.a | Neg | n.a | n.a | - |
| 35 | Neg | Neg | n.a | Neg | Neg | n.a | - |
| 43 | Eye signs | Neg | n.a | Neg | n.a | n.a | - |
| 46 | Neg | Neg | n.a | Neg | n.a | n.a | - |
| 52 | Neg | Neg | n.a | Neg | n.a | n.a | - |
| 54 | Neg | Neg | n.a | Neg | n.a | n.a | - |
| GOA | Neg | Neg | n.a | n.a | n.a | n.a | - |
| GON | Neg | Neg | n.a | n.a | n.a | n.a | - |
| VIA | Neg | Neg | n.a | n.a | n.a | n.a | - |
| ZAR | Neg | Neg | n.a | n.a | n.a | n.a | - |
| 9 | Lymphadenomegaly | 1:160 | n.a | Neg | Pos | n.a | + |
| 11 | Lymphadenomegaly | 1:320 | n.a | Neg | n.a | n.a | + |
| 23 | Skin signs, Lymphadenomegaly | 1:320 | n.a | Neg | Pos | n.a | + |
| 30 | Skin signs, Lymphadenomegaly | 1:320 | n.a | Neg | Neg | Bacterial contamination | + |
| 31 | Skin signs | 1:80 | n.a | Neg | Pos | n.a | + |
| 32 | Neg | 1:320 | n.a | Neg | Neg | n.a | + |
| 40 | Skin signs | 1:320 | n.a | Neg | Pos | n.a | + |
| 42 | Neg | 1:5120 | n.a | Neg | Pos | Pos | + |
| 45 | Neg | 1:40 | n.a | Neg | Pos | Bacterial contamination | + |
| 49 | Eye signs | 1:160 | n.a | Neg | n.a | n.a | + |
| 51 | Neg | Neg | n.a | Neg | Pos | n.a | + |
| 58 | Lymphadenomegaly | 1:2560 | n.a | Neg | Pos | n.a | + |
| 63 | Neg | 1:80 | n.a | Neg | Pos | n.a | + |
| 64 | Skin and eye signs, lymphadenomegaly | 1:2560 | n.a | Neg | Pos | Pos | + |
| STA-VOI | Mild periocular dermatisis, anemia, thrombocytopenia | n.a | Pos | n.a | n.a | n.a | + |
| MAI-EUI | Alopecia, weight loss, mild onychogryphosis, lymphadenomegal, leucopenia, decline in performance | n.a | Pos | n.a | n.a | n.a | + |
| MIA-MAI | Chronic anemia | n.a | Pos | n.a | n.a | n.a | + |
| KIO-MEI | Neg | n.a | Pos | n.a | n.a | n.a | + |
POS Positive NEG Negative, NA Data not available
Primers used in this study
| Target mRNA | Accession number | Forward primer (5’-3’) | Reverse primer (5’-3’) |
|---|---|---|---|
| Atf3 | XM_022420880.1 | TTCGCCATCCAGAACAAGCA | GGGCTACCTCAGTTTTCGTG |
| Atf4 | XM_854584.5 | TTCTCCAGCGACAAGGCTAA | AAGGCATCCTCCTTTCCGTTG |
| Ddit3 (Chop) | XM_014117187.2 | CTGGAAACAAGGAGGAAGAATCA | GGCTCTGGAAGGTGTTCGTG |
| Grid1 | XM_022417615.1 | TACAGCAAGGTGGCGAATCCT | AGGAGCACACAATGAGGGTGA |
| Hspa5 | XM_858292.5 | TGGCATAAACCCAGACGAGG | AGGGGACATACATCAAGCAGT |
| sXbp1 | XM_849540.5 | CTGAGTCCGCAGCAGGT | TGAACAGAATGCCCAACAGG |
| uXbp1 | XM_849540.5 | CCGCAGCACTCAGACTACG | TGAACAGAATGCCCAACAGG |
| Gapdh | NM_001003142.2 | GTCCCCACCCCCAATGTATC | TCCGATGCCTGCTTCACTAC |
Atf3 Canis lupus familiaris activating transcription factor 3, Atf4 Canis lupus familiaris activating transcription factor 4, Ddit3 Canis lupus familiaris DNA damage inducible transcript 3, Grid1 Canis lupus familiaris glutamate ionotropic receptor delta type subunit 1, Hspa5 Canis lupus familiaris heat shock protein family A (Hsp70) member 5, sXbp1 Canis lupus familiaris X-box binding protein 1 (spliced), uXbp1 Canis lupus familiaris X-box binding protein 1 (unspliced), Gapdh Canis lupus familiaris glyceraldehyde-3-phosphate dehydrogenase